The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Elizabeth B. Hirsch, PharmD, RPH, FIDSA
Advertisement
Hirsch is the current secretary of the Breakpoints Working Group of the CLSI Subcommittee on Antimicrobial Susceptibility Testing. She is also an associate professor at the University of Minnesota College of Pharmacy and runs the Hirsch laboratory in the Experimental and Clinical Pharmacology Department.
Articles by Elizabeth B. Hirsch, PharmD, RPH, FIDSA
This year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.
The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.
Updates include novel and revised breakpoints for azithromycin, polymyxins, daptomycin, and cefiderocol.
Advertisement
Latest Updated Articles
What’s New in 2022 From the CLSI Subcommittee on Antimicrobial Susceptibility TestingPublished: October 26th 2022 | Updated:
- What's New From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
Published: October 9th 2019 | Updated:
Advertisement
Advertisement
